🚀 VC round data is live in beta, check it out!
Collegium Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Collegium Pharmaceutical and similar public comparables like HBM Holdings, GuangYuYuan Chinese, GNI Group, Taysha GTx and more.
Collegium Pharmaceutical Overview
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Founded
2002
HQ
Employees
357
Website
Sectors
Financials (LTM)
EV
$2B
Collegium Pharmaceutical Financials
Collegium Pharmaceutical reported last 12-month revenue of $787M and EBITDA of $460M.
In the same LTM period, Collegium Pharmaceutical generated $690M in gross profit, $460M in EBITDA, and $291M in net income.
Revenue (LTM)
Collegium Pharmaceutical P&L
In the most recent fiscal year, Collegium Pharmaceutical reported revenue of $781M and EBITDA of $460M.
Collegium Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $787M | XXX | $781M | XXX | XXX | XXX |
| Gross Profit | $690M | XXX | $463M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $460M | XXX | $460M | XXX | XXX | XXX |
| EBITDA Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBIT Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| Net Profit | $291M | XXX | $289M | XXX | XXX | XXX |
| Net Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| Net Debt | — | — | $578M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Collegium Pharmaceutical Stock Performance
Collegium Pharmaceutical has current market cap of $1B, and enterprise value of $2B.
Market Cap Evolution
Collegium Pharmaceutical's stock price is $39.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $1B | 0.0% | XXX | XXX | XXX | $9.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCollegium Pharmaceutical Valuation Multiples
Collegium Pharmaceutical trades at 2.1x EV/Revenue multiple, and 3.7x EV/EBITDA.
EV / Revenue (LTM)
Collegium Pharmaceutical Financial Valuation Multiples
As of March 14, 2026, Collegium Pharmaceutical has market cap of $1B and EV of $2B.
Equity research analysts estimate Collegium Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Collegium Pharmaceutical has a P/E ratio of 4.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 3.7x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBIT | 3.7x | XXX | 3.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 4.3x | XXX | 4.3x | XXX | XXX | XXX |
| EV/FCF | 4.9x | XXX | 5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Collegium Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Collegium Pharmaceutical Margins & Growth Rates
Collegium Pharmaceutical's revenue in the last 12 month grew by 1%.
Collegium Pharmaceutical's revenue per employee in the last FY averaged $2.2M.
Collegium Pharmaceutical's rule of 40 is 60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Collegium Pharmaceutical's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Collegium Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Growth | (3%) | XXX | (0%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 60% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Collegium Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| HBM Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| GuangYuYuan Chinese | XXX | XXX | XXX | XXX | XXX | XXX |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Taysha GTx | XXX | XXX | XXX | XXX | XXX | XXX |
| China TCM | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Collegium Pharmaceutical M&A Activity
Collegium Pharmaceutical acquired XXX companies to date.
Last acquisition by Collegium Pharmaceutical was on XXXXXXXX, XXXXX. Collegium Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Collegium Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCollegium Pharmaceutical Investment Activity
Collegium Pharmaceutical invested in XXX companies to date.
Collegium Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Collegium Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Collegium Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Collegium Pharmaceutical
| When was Collegium Pharmaceutical founded? | Collegium Pharmaceutical was founded in 2002. |
| Where is Collegium Pharmaceutical headquartered? | Collegium Pharmaceutical is headquartered in United States. |
| How many employees does Collegium Pharmaceutical have? | As of today, Collegium Pharmaceutical has over 357 employees. |
| Who is the CEO of Collegium Pharmaceutical? | Collegium Pharmaceutical's CEO is Vikram Karnani. |
| Is Collegium Pharmaceutical publicly listed? | Yes, Collegium Pharmaceutical is a public company listed on Nasdaq. |
| What is the stock symbol of Collegium Pharmaceutical? | Collegium Pharmaceutical trades under COLL ticker. |
| When did Collegium Pharmaceutical go public? | Collegium Pharmaceutical went public in 2015. |
| Who are competitors of Collegium Pharmaceutical? | Collegium Pharmaceutical main competitors are HBM Holdings, GuangYuYuan Chinese, GNI Group, Taysha GTx. |
| What is the current market cap of Collegium Pharmaceutical? | Collegium Pharmaceutical's current market cap is $1B. |
| What is the current revenue of Collegium Pharmaceutical? | Collegium Pharmaceutical's last 12 months revenue is $787M. |
| What is the current revenue growth of Collegium Pharmaceutical? | Collegium Pharmaceutical revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Collegium Pharmaceutical? | Current revenue multiple of Collegium Pharmaceutical is 2.1x. |
| Is Collegium Pharmaceutical profitable? | Yes, Collegium Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Collegium Pharmaceutical? | Collegium Pharmaceutical's last 12 months EBITDA is $460M. |
| What is Collegium Pharmaceutical's EBITDA margin? | Collegium Pharmaceutical's last 12 months EBITDA margin is 59%. |
| What is the current EV/EBITDA multiple of Collegium Pharmaceutical? | Current EBITDA multiple of Collegium Pharmaceutical is 3.7x. |
| What is the current FCF of Collegium Pharmaceutical? | Collegium Pharmaceutical's last 12 months FCF is $341M. |
| What is Collegium Pharmaceutical's FCF margin? | Collegium Pharmaceutical's last 12 months FCF margin is 43%. |
| What is the current EV/FCF multiple of Collegium Pharmaceutical? | Current FCF multiple of Collegium Pharmaceutical is 4.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.